AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02390960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Cream
Description: Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
Study NCT02390960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
Study NCT02390960 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Penile Plethysmography (RigiScan)
Description: During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
Study NCT02390960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penile Plethysmography (RigiScan)
Description: During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
Study NCT06103019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional complete denture
Description: conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
Study NCT06103019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D complete denture
Description: 3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
Study NCT06269575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE NUTRITION PROGRAM
Description: Safe nutrition program:~patient education, caregiver training, behavioral swallowing intervention, position, oral care, swallowing exercises, swallowing assessment
Study NCT02871414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REST - Late Group
Description: Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
Study NCT02859168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Induction
Description: Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
Study NCT02859168 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Unplugged pulsed shortwave therapy
Description: Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
Study NCT03047057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: IV Lidocaine infusion
Study NCT03047057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: IV normal saline infusion
Study NCT02617381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: assessing the sensitivity and specificity of a simple structured questionnaire
Study NCT02956239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermocoagulation (device)
Description: Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
Study NCT02956239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy (device)
Description: Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
Study NCT02956239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP (device)
Description: The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
Study NCT02647814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salud al Día
Description: A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
Study NCT01099553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Instructions to view an educational video about preparing for a colonoscopy
Study NCT01099553 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Written instructions
Description: Written instructions on preparing for a colonoscopy
Study NCT02859311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of therapy
Description: Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
Study NCT03438747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-15L Bone Graft
Description: The investigational group will be treated with P-15L in an instrumented TLIF
Study NCT03438747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local autologous bone in a TLIF with Instrumentation
Description: The active control group will be treated local autologous bone in an instrumented TLIF
Study NCT02056496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
Study NCT02056496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
Study NCT03908580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
Study NCT00527072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
Study NCT01105936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 665 mg sustained release paracetamol caplets
Study NCT01105936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caplets
Study NCT01311739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyanocobalamin
Study NCT01311739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin
Study NCT02007252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: ACZ885 150 mg liquid pre-filled syringes were administered s.c..
Study NCT02007252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo liquid pre-filled syringes were administered s.c..
Study NCT02019498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation exercise
Description: Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
Study NCT02019498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ususal care
Description: Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
Study NCT00854438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary drug reviews by pharmacist and physician
Description: Reduction of anticholinergic drug effects by pharmacist review
Study NCT01197092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitochondrial preparations
Description: Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)
Study NCT01197092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infusion therapy
Description: Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
Study NCT01197092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Webermedical device
Description: Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
Study NCT01197092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts.
Study NCT01197092 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional therapy
Description: Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts.
Study NCT05156333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Respecta
Description: Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed.
Study NCT05156333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Respecta
Description: Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed.
Study NCT04107428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
Study NCT04107428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
Study NCT02072746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Study NCT02072746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03208075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal diet
Description: Diet containing 1500mg of phosphorus
Study NCT03208075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-phosphorus diet
Description: Diet containing 500mg of phosphorus
Study NCT03208075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-phosphorus diet
Description: Diet containing 2300mg of phosphorus
Study NCT00987610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: PCI for chronic total occlusion is performed using either arm of guidewire
Study NCT02001688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kamada-AAT for Inhalation, 80mg
Study NCT02001688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02001688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kamada-AAT for Inhalation, 160mg
Study NCT02311790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-C16:1 supplement
Description: Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
Study NCT02311790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cis-C16:1 supplement
Description: Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
Study NCT03189407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Moringa oleifera tea
Study NCT02848313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
Study NCT02003118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKR 202
Study NCT02003118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02530099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CN-group
Description: Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
Study NCT02530099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure-group
Description: Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
Study NCT02732249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Given 30 min before morning and evening meals
Study NCT02732249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Given 30 min before morning and evening meals
Study NCT02732249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Given 30 min before morning and evening meals
Study NCT02732249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given 30 min after morning and evening meals
Study NCT02732249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Given 30 min after morning and evening meals
Study NCT02732249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Given 30 min after meals or at bedtime
Study NCT02732249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Given 30 min after meals or at bedtime
Study NCT02152072 — intervention group
Intervention type: OTHER
Intervention: Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination
Study NCT02477306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idiazole 20mg DR tabs
Description: Delayed release tablets containing 20 mg of rabeprazole
Study NCT02477306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARIET 20 mg DR tabs
Description: Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
Study NCT01755325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound realgar natural indigo Tablet
Description: Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd
Study NCT01755325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03395041 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac imaging tests
Description: cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography
Study NCT02919917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
Study NCT02353676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
Study NCT02353676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SALINE
Description: 1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
Study NCT03049605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Only medical treatment
Description: Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
Study NCT00144664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Study NCT00895414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02289339 — intervention group
Intervention type: DEVICE
Intervention: aortic valve prostheses
Description: balloon-expandable and self-expandable aortic valve prostheses
Study NCT00895414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate
Description: Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
Study NCT04044911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task model (CogWatch)
Study NCT01637272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Description: Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
Study NCT02883270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Gait Training
Description: Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
Study NCT02883270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional rehabilitation
Description: The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
Study NCT03024060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: 20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
Study NCT02390687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
Study NCT03024060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
Study NCT03024060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IBL 20 mW
Description: 10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds